Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

GRAIL (GRAL) stock in plain English

Free brief · no signupStart here
GRALPublished Nov 18, 2026
GRAIL Inc
Healthcare · Diagnostics & Research
Sells multi-cancer early detection blood tests to healthcare providers and employers.
Assets:
Galleri testFlagship multi-cancer early detection assay screening over fifty cancer types
CLIA laboratoryHigh-throughput testing facility located in Research Triangle Park, North Carolina
NHS clinical trialLarge-scale randomized study evaluating population screening with over 140,000 participants
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

69
OPS ScoreOperating finances
Latest quote
+2.68%$104.84
$4.71B
n/a (loss)
$166.63M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was GRAL. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does GRAIL (GRAL) do?

GRAIL Inc (GRAL) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells multi-cancer early detection blood tests to healthcare providers and employers. Runs high-throughput genomic sequencing to detect early signals of over fifty cancer types from one blood draw. It is worth $4.71B on the market and sold $166.63M over the last year.

Market cap
$4.71B
P/E ratio
None (reported a loss)
Annual sales
$166.63M
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 18, 2026

Brands and businesses behind GRAL

  • Galleri: Sells blood tests that screen for multiple cancer signals and earns revenue per completed laboratory test order.

GRAL’s flags, in plain English

Each flag is a number from GRAIL’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 8.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 3% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Insiders Hold

Insiders own 5.6% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Burning Cash

Losing money, profit margin of -243.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about GRAL

How big is GRAIL?

GRAIL’s market cap is $4.71B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $166.63M: what customers paid the company over the last year, before any costs.

What is GRAL’s P/E ratio?

GRAL has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with GRAL?

The flagship Galleri test lacks full FDA approval and is currently marketed solely as a laboratory developed test. That is one risk on GRAIL’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From GRAIL’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. GRAL’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card